

A New Sterol Sulfate, Sch 572423, from a Marine Sponge, *Topsentia* sp.

Shu-Wei Yang,^{a,*} Alexei Buivich,^a Tze-Ming Chan,^a Michelle Smith,^a
Jean Lachowicz,^a Shirley A. Pomponi,^b Amy E. Wright,^b Ronald Mierzwa,^a
Mahesh Patel,^a Vincent Gullo^a and Min Chu^a

^aSchering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA

^bHarbor Branch Oceanographic Institution, 5600, U.S. 1 North, Fort Pierce, FL 34946, USA


Received 21 August 2002; accepted 6 February 2003

Abstract—Bioassay-guided fractionation of an active fraction from a marine sponge *Topsentia* sp. in our marine fraction library (MFL) led to the isolation and identification of halistanol sulfate (**1**) and a new sterol sulfate Sch 572423 (**2**). Compounds **1** and **2** were identified as P2Y₁₂ inhibitors with IC₅₀ of 0.48 and 2.2 μM, respectively. The general method of purification for the MFL library and the structure elucidation of compound **2** are described.

© 2003 Elsevier Science Ltd. All rights reserved.

Marine organisms are an excellent source of structurally diverse molecules which are potentially useful for drug discovery.¹ Several marine natural products have been discovered as new lead compounds in various therapeutical areas.^{2,3} The compounds derived from marine sources currently under clinical studies include bryostatin 1, dolastatin 10, LU-103793, ecteinascidin 743, aplidine (dehydrodidemnin B), discodermolide, TNP-470, and squalamine mainly in the anti-cancer area.^{2–4} In our marine natural product research program, we have built a marine fraction library (MFL) for high throughput screening (HTS) assays in different biological targets. The active fractions in various therapeutic areas were followed up using bioassay-guided fractionation to identify the active compounds.

Isolation and identification of active principals from the marine sponge *Topsentia* sp. (Halichondriidae) are described in this paper. In this study, a fraction was identified which bound to the P2Y₁₂ receptor. Followed by bioassay-guided fractionation of this active fraction, one new compound Sch 572423 (**2**) was discovered in addition to the principal active compound, halistanol sulfate (**1**).



Halistanol sulfate (**1**) R₁ = SO₃Na; R₂ = OSO₃Na; R₃ = R₄ = H

Sch 572423 (**2**) R₁ = SO₃Na; R₂ = H; R₃ = R₄ = OH

Sch 599469 (**3**) R₁ = H; R₂ = H; R₃ = R₄ = OH

Purinergic receptors of the P2Y subclass bind naturally occurring nucleotides and signal through G-proteins.⁵ P2Y₁ and P2Y₁₂ receptors are expressed in mammalian platelets. Activation of these receptors by ADP induces platelet aggregation.⁶ The molecular identity of the P2Y₁₂ receptor, which is the target of the antithrombotic thienopyridine clopidogrel, was recently established.^{7,8} Targeted deletion of this receptor gene in mice results in impaired platelet aggregation and prolonged bleeding time.⁹ Binding to the P2Y₁₂ receptor was evaluated as previously described using the radioligand [³H] 2-methylthio-ADP and 1321N cells stably expressing the receptor.⁹

The sponge was collected using the Johnson-Sea-Link I manned submersible at a depth of 240 feet off Andros Island, Bahamas (latitude 24°38.82'N, longitude 77°41.11'W). The sponge has not been described to the

*Corresponding author. Tel.: +1-908-740-7291; fax: +1-908-740-7152; e-mail: shu-wei.yang@spcorp.com

species level, however, it is characterized by a plate shape, firm consistency, and cream color. It was approximately 15 cm in diameter and 1.5 cm thick, attached to a rock overhang. The sponge has a dense choanosome and microhispid ectosome. It contains a spicule skeleton of oxeas in several size categories, some of which are bent. The sponge is identified as *Topsentia* sp.¹⁰ (Class: Demospongiae; Order: Halichondrida; Family: Halichondriidae). A reference sample preserved in ethanol has been deposited in the Harbor Branch Oceanographic Museum (catalog number 003:00990, DBMR number 25-XI-92-3-011) and is available for taxonomic evaluation.

In the primary HTS assay, a sample in the MFL from a marine sponge *Topsentia* sp. displaced [³H] 2-Me-S-ADP binding to the P2Y₁₂ receptor with 93% displacement at 20 µg/mL. Therefore, the active fraction was subjected to bioassay-guided fractionation. The general procedure for generation of the primary fractions in the marine fraction library was conducted as follows: Crude sample (100–200 g) was ground and extracted with ethanol. The dried organic extract was fractionated on a CG161 column (~60 mL) to generate 6 fractions eluting with aqueous acetonitrile (ACN) gradient solution (10, 25, 50, 75, 100%) and followed by eluting with methanol–EtOAc. All fractions were dried and part of the material was submitted for HTS assay. In this study, fraction 3 (50% ACN elution) was active in the P2Y₁₂ binding assay. Fraction 3 (35 mg) was further purified on an HPLC semi-preparative ODS-A column (YMC, 120 Å, S-7, 2×25 cm). The column was eluted with gradient aqueous ACN system (3–50% ACN over 70 min), to yield 100 fractions (13 mL/fraction). Two pure compounds **2** (2.7 mg) and **1** (13 mg) were obtained with retention time ~37 and ~62 min, respectively.

The structure of compound **1** was identified as halistanol sulfate based on detailed NMR and MS analysis.¹¹ The ion peak of [M–Na]⁺ of **1** was detected in high-resolution negative FABMS (obsd. *m/z* 731.2195; calcd *m/z* 731.2182 for C₂₉H₄₉O₁₂S₃Na₂). The proton and carbon NMR data analysis further indicated that **1** is identical to halistanol sulfate as reported in the literature.¹²

The structure of compound **2** was determined based on extensive NMR and HRMS analyses and by comparison with compound **1** (Table 1). From the high-resolution negative FABMS, the molecular formula of **2** was established as C₂₉H₅₀O₁₀S₂Na₂ (obsd. 645.2758; calcd 645.2744 for [M–Na]⁺ of C₂₉H₅₀O₁₀S₂Na). All spectral data including HRMS, ¹H and ¹³C NMR data strongly suggested that compound **2** was structurally related to **1**, and indicated the presence of two sulfate ester groups in the molecule. The overlapping ¹H and ¹³C signals of three methyl groups indicated the presence of a *t*-butyl group in the molecule. The location of two hydroxyl groups on the side chain was determined by analysis of HMBC and HSQC–TOCSY data. In the HMBC spectrum, *O*-substituted C-22 (δ 75.7) and C-23 (δ 74.1) had three bond H–C couplings with H₃-21 (δ 0.90), and H₃-26 (δ 0.84), respectively. In addition, H–C two-bond correlations observed below from HSQC–TOCSY data

Table 1. NMR spectral data for compounds Sch 572423 (**2**) in CD₃OD

No.	¹ H (J)	¹³ C	HSQC– TOCSY (2 bond)	HMBC (C no.)	NOE correlations from ROESY
1α	1.39, m	39.3 t	C-2		H ₃ -19
1β	2.07, brd, (14.6)				
2	4.72, br s	76.6 d	C-1		
3	4.69, br s	76.3 d	C-4		
4α	1.60, m	30.6 t	C-5		H ₃ -19
4β	1.79, td (12.8, 2.2)				
5	1.58, m	40.3 d	C-6		
6	1.26, m	29.3 t	C-5, 7		
7	0.94, m 1.68, m	33.4 t	C-6, 8		
8	1.40, m	36.6 d	C-7, 9		H ₃ -18, H ₃ -19
9	0.71, m	56.8 d	C-11		
10		36.6 s			
11β					
11α	1.32, m				
	1.52, m	22.2 t	C-9, 12		H ₃ -18, H ₃ -19
12α	1.17, m	41.7 t	C-11		H-14
12β	1.99, brd, (12.7)				H ₃ -18, H ₃ -21
13		43.9 s			
14	1.08, m	58.1 d	C-8		H-12α, H-17
15β	1.08, m	25.3 t	C-16		
15α	1.60, m				
16β	1.31, m	28.7 t	C-15, 17		H-22
16α	1.90, m				
17	1.49, m	54.1 d	C-20		H-14, H ₃ -21
18	0.71, s	12.7 q		12, 13, 14, 17	H-11β, H-12β, H-17β, H-20, H ₃ -21
19	0.99, s	14.5 q		1, 5, 9, 10	H-1β, H-4β, H-8, H-11β
20	1.86, m	37.4 d	C-17, 21		H ₃ -18, H-23
21	0.90, d, (6.8)	12.4 q		17, 20, 22	H-12β, H-17, H ₃ -18, H-23
22	3.43, d, (9.7)	75.7 d	C-23	21, 23	H ₂ -16, H-24, H ₃ -26
23	3.79, d, (9.7)	74.1 d	C-22	22, 25, 26	H ₃ -21
24	1.65, m	43.3 d	C-26		H-22, H ₃ -27, H ₃ -28, H ₃ -29
25		34.1 s			
26	0.84, d, (7.1)	8.2, q	C-24	23, 24, 25	H-22, H ₃ -27, H ₃ -28, H ₃ -29
27	0.93, s	29.0 q		24, 25, 28, 29	H-24, H ₃ -26
28	0.93, s	29.0 q		24, 25, 27, 29	H-24, H ₃ -26
29	0.93, s	29.0 q		24, 25, 27, 28	H-24, H ₃ -26

δ in ppm; J in Hz.

allowed us to determine and assign the side-chain structure: H-20/C-17, C-21; H-22/C-23; H-23/C-22; H-24/C-26 (see Fig. 1).

The sterol skeleton was confirmed using a similar method with analyses of HMBC and HSQC–TOCSY data. The connection of the consecutive protonated carbons in sterol skeleton was completed through two-bond H–C correlations by analysis of HSQC–TOCSY data. The connectivity of quaternary carbons C-10 and C-13 to their neighboring carbons were determined by HMBC through H₃-18 and H₃-19, respectively, as shown in Figure 1. Therefore, the full skeleton of sterol **2** was determined. The two sulfate ester groups were




Figure 1.

Table 2. NMR spectral data for compounds Sch 599469 (**3**)

No.	¹ H (δ)	¹³ C (δ)	No.	¹ H (δ)	¹³ C (δ)
1	1.51, m	40.5	16	1.31, m	27.7
	1.73, m			1.88, m	
2	3.91, br s	71.8	17	1.42, m	52.7
3	3.87, br s	70.6	18	0.70, s	12.1
4	1.33, 1.90	31.7	19	0.99, s	14.6
5	1.56, m	38.9	20	1.89, m	36.0
6	1.26, m	29.7	21	0.94, <i>J</i> =7.4	11.6
7	0.93, m	31.9	22	3.45, <i>J</i> =9.2	73.6
	1.67, m				
8	1.38, m	35.0	23	3.79, <i>J</i> =9.2	70.9
9	0.73, m	55.1	24	1.71, m	42.3
10		35.7	25		33.1
11	1.28, m	20.9	26	0.85, <i>J</i> =7.5	7.5
	1.52, m				
12	1.17, m	40.1	27	0.95, s	28.2
	1.97, m				
13		42.7	28	0.95, s	28.2
14	1.08, m	56.4	29	0.95, s	28.2
15	1.09, m	24.0			
	1.61, m				


Recorded in CDCl₃; δ in ppm; *J* in Hz.

assigned to C-2 and C-3 based on their carbon chemical shifts, comparing to those of halistanol sulfate derivatives and the hydrolysis product **3** (Table 2, see below for detail).^{12–17}

The stereochemistry of 2- and 3-position was determined as *trans* configuration by the coupling pattern of H-2 (br s) and H-3 (br s). The ¹H and ¹³C chemical shifts and NOE data confirmed the *trans* configuration of all the ring junctions, which were consistent with those of halistanol sulfate (**1**).^{12,13} The stereochemistry of side chain of **2** was proposed as 20*S*, 22*R*, 23*R*, and 24*S* based on the ¹H–¹H *J* couplings and NOE data with comparison to those of brassinolide (**4**), which stereochemistry was determined by X-ray crystallography.¹⁸ The large *J* coupling constants of H-22 and H-23 (9.2 Hz) indicated that these two protons had *anti* conformation. The small *J* couplings (*J* ≤ 1 Hz) between H-20 and H-22 and between H-23 and H-24 suggested that the dihedral angles were near 90° for both proton pairs. These data were identical to those observed in the side chain of brassinolide (*J*=8.4 Hz for H-22 and H-23; *J* ≤ 1 Hz for H-20 and H-22 and for H-23 and H-24, respectively).^{16,17} The proposed stereochemistry was further supported by the observation of the following

NOE correlations shown in the ROESY spectrum: H₃-18 to H-20; H₃-21 to H-23, H-12β, H-17, and H₃-18; H-22 to H-24, H₃-26, H-16α, and H-16β; H-24 to H₃-27, H₃-28, and H₃-29.^{14,16,17}

Since compound **2** was insoluble in CDCl₃ and most of the NMR data of brassinolide analogues were obtained in CDCl₃, hydrolysis product of **2**, Sch 599469 (**3**),¹⁹ was prepared in order to compare NMR data to those of brassinolide analogues in the same solvent. ¹H and ¹³C NMR assignments of compound **3** were accomplished based on extensive spectroscopic data analyses including HMBC, HSQC, and HSQC-TOCSY. The coupling constants, *J*=9.2 Hz for H-22/H-23, *J* ≤ 1 Hz for H-20/H-22, and *J* ≤ 1 Hz for H-23/H-24 in compound **3** were virtually identical to those of the synthetic analogue of **4**, 25-methylbrassinolide (**5**), which has the same side chain as those of compounds **2** and **3** (*J*=9.0 Hz for H-22/H-23; *J* ≤ 1 Hz for H-20/H-22; *J* ≤ 1 Hz for H-23/H-24, as reported in the literature for **5**).^{20,21} The NOE data obtained from a ROESY experiment for **3** further confirmed the above stereochemistry assignments (NOE: H₃-21 to H-23, H-12β, H-17, and H₃-18; H-22 to H-24, H₃-26, H-16α, and H-16β; H-24 to H₃-27, H₃-28, and H₃-29).



Sch599469 (**3**) R₁ = OH; R₂ = H; R₃ = CH₃; X = CH₂

Brassinolide (**4**) R₁ = H; R₂ = OH; R₃ = H; X = COO

25-Methylbrassinolide (**5**) R₁ = H; R₂ = OH; R₃ = CH₃; X = COO

Compounds **1** and **2** exhibited fairly potent inhibitory activity in the P2Y₁₂ assay. The IC₅₀ values of **1** and **2** binding to the P2Y₁₂ receptor were 0.48 and 2.2 μM, respectively.

Acknowledgements

The authors wish to acknowledge Dr. David Powell for HRFAB mass measurements at the Mass Spectrometry Center in the Department of Chemistry, University of Florida. Thanks to Harbor Branch Oceanographic Institution for providing the marine samples and extracts. The authors also wish to thank Dr. Ling He for mass spectral work.

References and Notes

- For review see: Faulkner, D. J. *Nat. Prod. Rep.* **2001**, *18*, 1.
- Kerr, R. G.; Kerr, S. S. *Exp. Opin. Ther. Pat.* **1999**, *9*, 1207.
- Shu, Y.-Z. *J. Nat. Prod.* **1998**, *61*, 1053.
- Logothetis, C. J.; Wu, K. K.; Finn, L. D.; Daliani, D.; Figg, W.; Ghaddar, H.; Gutterman, J. U. *Clin. Cancer Res.* **2001**, *7*, 1198.
- von Kügelgen, I.; Wetter, A. *Naunyn Schmiedeberg's Arch Pharmacol.* **2000**, *362*, 310.
- Gachet, C. *Ann. Med.* **2000**, *32* (Suppl 1), 15.

7. Zhang, F. L.; Luo, L.; Gustafson, E.; Lachowicz, J.; Smith, M.; Qiao, X.; Liu, Y. H.; Chen, G.; Pramanik, B.; Laz, T. M.; Palmer, K.; Bayne, M.; Monsma, F. J., Jr. *J. Biol. Chem.* **2001**, 276, 8608.
8. Hollopeter, G.; Jantzen, H. M.; Vincent, D.; Li, G.; England, L.; Ramakrishnan, V.; Yang, R. B.; Nurden, P.; Nurden, A.; Julius, D.; Conley, P. B. *Nature* **2001**, 409, 202.
9. Foster, C. J.; Prosser, D. M.; Agans, J. M.; Zhai, Y.; Smith, M. D.; Lachowicz, J. E.; Zhang, F. L.; Gustafson, E.; Monsma, F. J., Jr.; Wiekowski, M. T.; Abbondanzo, S. J.; Cook, D. N.; Bayne, M. L.; Lira, S. A.; Chintala, M. S. *J. Clin. Invest.* **2001**, 107, 1591.
10. Soest, R. W. M.; Diaz van, M. C.; Pomponi, S. A. *Beaufortia* **1990**, 40, 15.
11. General Experimental Procedures: NMR spectra were recorded in methanol- d_4 or $CDCl_3$ on a Varian Unity 500 NMR instrument at 500 MHz for 1H and 125 MHz for ^{13}C , using standard Varian pulse sequence programs (VNMR Version 6.1 Software). FABMS was performed on a Finnigan MAT95Q hybrid sector mass spectrometry (ThermoFinnigan, San Jose, CA) in negative ion mode liquid secondary ion mass spectrometry (LSIMS).
12. Fusetani, N.; Matsunaga, S.; Konosu, S. *Tetrahedron Lett.* **1981**, 22, 1985.
13. Kanazawa, S.; Fusetani, N.; Matsunaga, S. *Tetrahedron* **1992**, 48, 5467.
14. Fu, X.; Ferreira, M. L. G.; Schmitz, F. J.; Kelly, M. *J. Org. Chem.* **1999**, 64, 6706.
15. D'Auria, M. V.; Riccio, R.; Minale, L.; La Barre, S.; Pusset, J. *J. Org. Chem.* **1987**, 52, 3947.
16. Stoldt, M.; Porzel, A.; Adam, G.; Brandt, W. *Magn. Reson. Chem.* **1997**, 35, 629.
17. Porzel, A.; Marquardt, V.; Adam, G.; Massiot, G.; Zeigan, D. *Magn. Reson. Chem.* **1992**, 30, 651.
18. Grove, M. D.; Spencer, G. F.; Rohwedder, W. K.; Mandava, N.; Worley, J. F.; Warthen, J. D., Jr.; Steffens, G. L.; Flippen-Anderson, J. L.; Cook, J. C., Jr. *Nature* **1979**, 281, 216.
19. Compound **2** (1.2 mg) in 100 μ L 1 N HCl, was refluxed for 30 min. The mixture was cooled to rt, and then extracted with EtOAc. EtOAc extract was dried by Na_2SO_4 , and after filtration solvent was removed by evaporation. Sch 599469 (**3**, 1 mg) was obtained.
20. Mori, K.; Takeuchi, T. *Liebigs Ann. Chem.* **1988**, 815.
21. Zhou, W.-S.; Huang, L.-F. *Tetrahedron* **1992**, 48, 1837.